Abstract：Objective: To explore the relationship between serum thyroid stimulating hormone (TSH) and cervical lymph node metastasis of thyroid papillary carcinoma (PTC), in order to provide a theoretical basis for clinical diagnosis and treatment. Methods: The clinical data (observation group) of 80 patients with pathologically confirmed PTC admitted to our hospital from September 2013 to August 2018,In the same period, the clinical data (control group) of 62 patients who were diagnosed as benign thyroid nodules after treatment in our hospital were included.The general clinical data of the two groups were compared. Serum thyroid stimulating hormone (TSH) levels were compared between the two groups. The levels of TSH in different pathological data were compared. Results: A total of 80 patients in the observation group and 62 patients in the control group were included. There was no significant difference in the general clinical data between the two groups (P>0.05). Serum TSH (2.3±0.6 uIU/ml VS 1.1±0.4 uIU/ml; t=13.58, P<0.01) was significantly higher in the observation group than in the control group (P<0.05). There was no significant difference in serum TSH levels between the different pathological data in the observation group (P>0.05). There were significant differences in calcification, TNM stage, tumor diameter, and cervical lymph node metastasis. (P<0.05). Conclusion: Serum TSH has a certain correlation with PTC cervical lymph node metastasis, and it has certain clinical application value for the diagnosis and treatment of assisted PTC.
[1] Jo K, Lim DJ. Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer[J].Korean Intern Med,2018,33(6):1050~1057. [2] Veedu JS, Mathew A. Are we missing the elephant in the room a case for thyroid cancer overdiagnosis as the etiology for its increasing incidence in india[J].Glob Oncol,2018,(4): 1~3. [3] Abraham E, Tran B, Roshan D, et al. Response to Re: Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence[J].ANZ Surg,2018,88(11): 1212~1213. [4] Xia F, Chen Y, Jiang B, et al. Long noncoding RNA HOXA-AS2 promotes papillary thyroid cancer progression by regulating miR-520c-3p/S100A4 pathway[J].Cell Physiol Biochem,2018,50(5): 1659~1672. [5] Lin YH, Wu MH, Huang YH, et al. Thyroid hormone negatively regulates tumorigenesis through suppression of BC200[J].Endocr Relat Cancer,2018,25(12): 967~979. [6] Hwangbo Y, Lee EK, Son HY, et al. Genome-wide association study reveals distinct genetic susceptibility of thyroid nodules from thyroid cancer[J].Clin Endocrinol Metab,2018,103(12): 4384~4394. [7] Damiani L, Lupo S, Rossi R, et al. Evaluation of the role of BRAFV600E somatic mutation on papillary thyroid cancer disease persistence: a prospective study[J].Eur Thyroid,2018,7(5): 251~257. [8] Zheng G, Zhang H, Hao S, et al. Patterns and clinical significance of cervical lymph node metastasis in papillary thyroid cancer patients with Delphian lymph node metastasis[J].Oncotarget,2017,8(34): 57089~57098. [9] Guo F, Hou X, Sun Q. MicroRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF[J].Oncol Lett,2018,16(5): 6815~6821.
2019, Vol. 25 
冀公网安备13080202000677号